KRAS and neoplasm: It is now clearly established that activating mutations in Kras are found in the majority of PCs and that these mutations, along with other genetic lesions, contribute to the increased aggressiveness of the tumour (Almoguera et al, 1988; Dergham et al, 1997; Wang et al, 2002; Aguirre et al, 2003; Hezel et al, 2006).